# A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

> **NCT05305222** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 17 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05305222
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-23
- **Primary completion:** 2018-06-15
- **Final completion:** 2018-06-15
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05305222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05305222, "A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05305222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*